Purchase this article with an account.
H-H Koh, IJ Murray, JW Feather, D Carden, DJ Nolan; Macular Pigment Optical Density in Early, Age-Related Maculopathy (ARM); Comparisons With Normals and Effects of a Lutein Supplement . Invest. Ophthalmol. Vis. Sci. 2002;43(13):2562.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose: To compare Macular Pigment (MP) optical density in a group of early ARM patients with normals and to determine the effect on MP optical density of a Lutein supplement in both groups. Methods: In the first study, 8 patients (age range 60-81, normal visual acuity) with early ARM (soft drusen) were compared with normals matched for sex, eye-colour and age. In a second (on-going) study MP optical density is being measured in 8 patients (6 from first group) and 6 normals who are taking 20mg Lutein ester tablets (equivalent to 10mg free Lutein) per day over a 18 week period. MP optical density is determined using a purpose built device which allows free-viewing of the 1° stimulus. The target is composed of two groups of 3 LEDs, viewed through a diffuser and alternated at 25Hz. Peak wavelengths of the LEDs are 525nm and 470nm. Mean luminance of the 525nm (green) light is 75cd/m2. Subjects/patients set flicker thresholds by varying the intensity of the 470nm (blue) light, when viewing the target at either 0 or 5° eccentricity. MP optical density is defined as the log ratio of the flicker threshold luminances of the 470nm light at the two eccentricities. Results: ARM fellow (unaffected) eyes had significantly lower MP optical density than normals (p = 0.025). After 12 weeks of the Lutein supplement the increase in MP optical density was slightly greater in the normals than the patients. This difference did not reach statistical significance. In the 8 cases of unilateral ARM, both right and left eyes showed a similar increase in MP optical density. Conclusion: We conclude, as in a previous study, that eyes at risk of developing ARM have lower MP optical density than those at no such risk. The data add credibility to the prospective protective role of MP. Second, affected and fellow ARM patients' eyes respond equally to a lutein supplement suggesting that, at least in the early stages of ARM, the disease does not impede the deposition of Lutein in the retina. Acknowledgement: This project was funded by the Department of Health, UK and Tinsley Instruments Limited. Lutein capsules were supplied by Cognis Corporation, USA.
This PDF is available to Subscribers Only